TF-TAVR significantly reduced in-hospital mortality (RR 0.65) compared to SAVR in patients aged 60-75 with severe aortic stenosis, though it was associated with higher reimbursement costs.
Cohort
Yes
Does TF-TAVR improve in-hospital outcomes and cost-effectiveness compared to SAVR in younger patients?
Younger patients undergoing aortic valve replacement
Transfemoral transcatheter aortic valve replacement (TF-TAVR)
Surgical aortic valve replacement (SAVR)
In-hospital outcomes and cost-effectiveness
A shift from SAVR to TF-TAVR in younger patients appears to be cost-effective with justifiable incremental costs per life saved.
Given an estimated life expectancy of 11 to 25 years in this population, the incremental costs per life saved associated with a hypothetical shift from SAVR to TF-TAVR appear justifiable. Nonetheless, individual patient circumstances must always be considered in decision-making.
Building similarity graph...
Analyzing shared references across papers
Loading...
Klaus Kaier
C. Von Zur Mühlen
Derek Hazard
Clinical Research in Cardiology
University of Freiburg
University Medical Center Freiburg
Universitäts-Herzzentrum Freiburg-Bad Krozingen
Building similarity graph...
Analyzing shared references across papers
Loading...
Kaier et al. (Mon,) conducted a cohort in Severe aortic stenosis (n=28,805). Transfemoral transcatheter aortic valve replacement (TF-TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on In-hospital mortality (RR 0.65, p=0.012). TF-TAVR significantly reduced in-hospital mortality (RR 0.65) compared to SAVR in patients aged 60-75 with severe aortic stenosis, though it was associated with higher reimbursement costs.
www.synapsesocial.com/papers/69df2bece4eeef8a2a6b0d58 — DOI: https://doi.org/10.1007/s00392-026-02911-9